Until now, treatment for eye disorders and other related problems were administered through injections, which were not only unpleasant but expensive as well. However, this would very soon become obsolete since researchers at University College London (UCL) have come up with eye drops for procuring macular degeneration.
Nearly 2 in 10 people over 75 have age-related macular degeneration. And at this point of time, the research would prove a boon in combating the growing numbers of patients, and especially when the escalating demands of eye injections becomes responsible for halting the progression of the malady.
The research showed the possibility of formulating substance with nanoparticles sodden with AMD drug Avastin and delivering it into the eyes. Professor Cordeiro, from UCL Institute of Ophthalmology envisions a promising future of the formulation fabricated by the nanotechnology.
The conventional treatment includes injecting medication into the eyes of patients for 24 consecutive months. This is not only cumbersome for the sufferers but many prefer detesting the expensive treatment. The National Health Service is already saturated with the number of people undergoing the treatment and the number would rise exponentially by the next decade.
Anatomical barriers especially in ophthalmology have always made it difficult to administer the medication into the retina. However, initially it was also thought that molecules of Avastin and Lucentis might have large structures because of which it couldn’t be administered via drops but the new research thwarted the belief.
UCL Business has already patented the nanotechnology for curing eye disorders and currently, the researchers are looking forward to commercial partnerships for accelerating development.